Acute hepatitis C: Prevention and treatment

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 3, 2009, Pages 351-361

  Ozaras, Resat ^a   Tahan, Veysel ^b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Pasabahce State Hospital   (Turkey)

Author keywords

Acute hepatitis C; Pegylated interferon; Spontaneous clearance

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; BETA INTERFERON; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; VIRUS RNA;

ACUTE HEPATITIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY DETECTION; BLOOD TRANSFUSION; CELLULAR IMMUNITY; DRUG EFFICACY; ENVIRONMENTAL EXPOSURE; FAMILIAL DISEASE; HEMOLYTIC ANEMIA; HEPATITIS C; HOSPITAL INFECTION; HUMAN; HUMORAL IMMUNITY; IMMUNOBIOLOGY; INCIDENCE; INFECTION RATE; INTRAVENOUS DRUG ABUSE; JAUNDICE; NONHUMAN; OCCUPATIONAL EXPOSURE; PATIENT COMPLIANCE; POLYMERASE CHAIN REACTION; PREVALENCE; REVIEW; SEXUAL TRANSMISSION; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; VIRUS TRANSMISSION; ACUTE DISEASE; ADULT; BLOOD; CHILD; DRUG EFFECT; FEMALE; GENETICS; HEPATITIS C VIRUS; ISOLATION AND PURIFICATION; MALE; VIROLOGY;

ACUTE DISEASE; ADULT; ANTIVIRAL AGENTS; CHILD; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; MALE; POLYETHYLENE GLYCOLS; RNA, VIRAL; YOUNG ADULT;

EID: 85047685704     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.09.8     Document Type: Review

References (115)

1. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 26(Suppl. 1), S2-S10 (1997).
2. Maheshwari A, Ray S, Thuluvath PJ. Acute hepatitis C. Lancet 372 (9635), 321-332 (2008).
3. Lorenz R, Endres S. Diagnosis and treatment of acute hepatitis C in adults. UpToDate Online 16.2.
4. Kamal SM. Acute hepatitis C: a systematic review. Am. J. Gastroenterol. 103(5), 1283-1297 (2008).
5. Alter MJ. Epidemiology of hepatitis C virus infection. World J. Gastroenterol. 13(17), 2436-2441 (2007).
6. Wasley A, Miller JT, Finelli L. Surveillance for acute viral hepatitis - United States, 2005. MMWR Surveill. Summ. 56(3), 1-24 (2007).
7. Spada E, Mele A, Ciccozzi M et al. Changing epidemiology of parenterally transmitted viral hepatitis: results from the hepatitis surveillance system in Italy. Dig. Liver Dis. 33(9), 778-784 (2001).
8. The Global Burden of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J. Clin. Pharmacol. 44(1), 20-29 (2004).
9. Desenclos JC. The challenge of hepatitis C surveillance in Europe. Euro. Surveill. 8(5), 99-100 (2003).
10. Sun CA, Chen HC, Lu SN et al. Persistent hyperendemicity of hepatitis C virus infection in Taiwan: the important role of iatrogenic risk factors. J. Med. Virol. 65(1), 30-34 (2001).
11. Okayama A, Stuver SO, Tabor E et al. Incident hepatitis C virus infection in a community-based population in Japan. J. Viral Hepat. 9(1), 43-51 (2002).
12. Mohamed MK, Abdel-Hamid M, Mikhail NN et al. Intrafamilial transmission of hepatitis C in Egypt. Hepatology 42(3), 683-487 (2005).
13. Zakaria S, Fouad R, Shaker O et al. Changing patterns of acute viral hepatitis at a major urban referral center in Egypt. Clin. Infect. Dis. 44(4), e30-e36 (2007).
14. Meky FA, Stoszek SK, Abdel-Hamid M et al. Active surveillance for acute viral hepatitis in rural villages in the Nile Delta. Clin. Infect. Dis. 42(5), 628-633 (2006).
15. Akcam FZ, Uskun E, Avsar K, Songur Y. Hepatitis B virus and hepatitis C virus seroprevalence in rural areas of the southwestern region of Turkey. Int. J. Infect. Dis. 13(2), 274-284 (2009).
16. Gurol E, Saban C, Oral O, Cigdem A, Armagan A. Trends in hepatitis B and hepatitis C virus among blood donors over 16 years in Turkey. Eur. J. Epidemiol. 21(4), 299-305 (2006).
17. Afsar I, Gungor S, Sener AG, Yurtsever SG. The prevalence of HBV, HCV and HIV infections among blood donors in Izmir, Turkey. Indian J. Med. Microbiol. 26(3), 288-289 (2008).
18. Bianco E, Stroffolini T, Spada E et al.; SEIEVA Collaborating Group. Case fatality rate of acute viral hepatitis in Italy: 1995-2000. An update. Dig. Liver Dis. 35(6), 404-408 (2003).
19. Hoofnagle JH, Carithers RL, Shapiro C, Ascher N. Fulminant hepatic failure: Summary of a workshop. Hepatology 21(1), 240 (1995).
20. Chu CM, Yeh CT, Liaw YF. Fulminant hepatic failure in acute hepatitis C: Increased risk in chronic carriers of hepatitis B virus. Gut 45(4), 613 (1999).
21. Vogt M, Lang T, Frösner G et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N. Engl. J. Med. 341(12), 866-870 (1999).
22. Seeff LB, Hollinger FB, Alter HJ et al. Long-term mortality and morbidity of transfusion-associated nbn-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study. Hepatology 33(2), 455-463 (2001).
23. Alter HJ, Conry-Cantilena C, Melpolder J et al. Hepatitis C in asymptomatic blood donors. Hepatology 26(3 Suppl. 1), S29-S33 (1997).
24. Thomas DL, Astemborski J, Rai RM et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 284(4), 450-456 (2000).
25. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 29(3), 908-914 (1999).
26. Marcellin P. Hepatitis C: the clinical spectrum of the disease. J. Hepatol. 31(Suppl. 1), 9-16 (1999).
27. Santantonio T, Wiegand J, Gerlach JT. Acute hepatitis C: current status and remaining challenges. J. Hepatol. 49(4), 625-633 (2008).
28. Hofer H, Watkins-Riedel T, Janata O et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology 37(1), 60-64 (2003).
29. Gerlach JT, Diepolder HM, Zachoval R et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 125(1), 80-88 (2003).
30. Blackard JT, Shata MT, Shire NJ, Sherman KE. Acute hepatitis C virus infection: a chronic problem. Hepatology 47(1), 321-331 (2008).
31. Shata MT, Anthony DD, Carlson NL et al. Characterization of the immune response against hepatitis C infection in recovered, and chronically infected chimpanzees. J. Viral Hepat. 9(6), 400-410 (2002).
32. Klenerman P, Lucas M, Barnes E, Harcourt G. Immunity to hepatitis C virus: stunned but not defeated. Microbes Infect. 4(1), 57-65 (2002).
33. Nelson DR, Marousis CG, Davis GL et al. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J. Immunol. 158(3), 1473-1481 (1997).
34. Erickson AL, Houghton M, Choo QL et al. Hepatitis C virus-specific CTL responses in the liver of chimpanzees with acute and chronic hepatitis C. J. Immunol. 151(8), 4189-4199 (1993).
35. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J. Viral Hepat. 13(1), 34-41 (2006).
36. Corey KE, Ross AS, Wurcel A et al. Outcomes and treatment of acute hepatitis C virus infection in a United States population. Clin. Gastroenterol. Hepatol. 4(10), 1278-1282 (2006).
37. Jonas M. Children with hepatitis C. Hepatology 36(Suppl. 1), S173-S178 (2002).
38. Lehmann M, Meyer MF, Monazahian M et al. High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection. J. Med. Virol. 73(3), 387-391 (2004).
39. Bakr I, Rekacewicz C, El Hosseiny M et al. Higher clearance of hepatitis C virus infection in females compared with males. Gut 55(8), 1183-1187 (2006).
40. Wang C, Krantz E, Klarquist J et al. Acute hepatitis C in a contemporary US cohort: Modes of acquisition and factors influencing viral clearance. J. Infect. Dis. 196(10), 1474-1482 (2007).
41. Kamal SM, Turner B, He Q et al. Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. Hepatology 43(4), 771-779 (2006).
42. Wells JT, Lucey MR, Said A. Hepatitis C in transplant recipients of solid organs, other than liver. Clin. Liver Dis. 10(4), 901-917 (2006).
43. Irshad M, Khushboo I, Singh S et al. Hepatitis C virus (HCV): a review of immunological aspects. Int. Rev. Immunol. 27(6), 497-517 (2008).
44. Spengler U, Lechmann M, Irrgang B et al. Immune responses in hepatitis C virus infection. J. Hepatol. 24(2 Suppl.), 20-25 (1996).
45. Chen M, Sällberg M, Sönnerborg A et al. Limited humoral immunity in hepatitis C virus infection. Gastroenterology 116(1), 135-143 (1999).
46. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436, 946-952 (2005).
47. Ishii S, Koziel MJ. Immune responses during acute and chronic infection with hepatitis C virus. Clin. Immunol. 128(2), 133-147 (2008).
48. Tsai SL, Liaw YF, Chen MH et al. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 25, 449-458 (1997).
49. Chang KM. Immunopathogenesis of hepatitis C virus infection. Clin. Liver Dis. 7(1), 89-105 (2003).
50. + T cells by flow cytometry: correlation with clinical disease stages. Hepatology 35, 190-198 (2002).
51. Missale G, Cariani E, Ferrari C. Role of viral and host factors in HCV persistence: which lesson for therapeutic and preventive strategies? Dig. Liver Dis. 36(11), 703-711 (2004).
52. + T cells. J. Exp. Med. 178, 1655-1663 (1993).
53. Luft T, Pang KC, Thomas E et al. Type I IFNs enhance the terminal differentiation of dendritic cells. J. Immunol. 161, 1947-1953 (1998).
54. Rosen HR, Weston SJ, Im K et al. Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy. Hepatology 46, 350-358 (2007).
55. Randall G, Chen L, Panis M et al. Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. Gastroenterology 131, 1584-1591 (2006).
56. Chen L, Borozan I, Feld J et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128, 1437-1444 (2005).
57. Luby S, Khanani R, Zia M et al. Evaluation of blood bank practices in Karachi, Pakistan, and the government's response. Health Policy Plan. 15(2), 217-222 (2000).
58. Kapoor D, Saxena R, Sood B, Sarin SK. Blood transfusion practices in India: result.; of a national survey. Indian J. Gastroenterol. 19(2), 64-67 (2000).
59. Cruz JR, Pérez-Rosales MD, Zicker F, Schmunis GA. Safety of blood supply in the Caribbean countries: role of screening blood donors for markers of hepatitis B and C viruses. J. Clin. Virol. 34(Suppl. 2), S75-S80 (2005).
60. Madhava V, Burgess C, Drucker E. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect. Dis. 2(5), 293-302 (2002).
61. Hahn JA, Page-Shafer K, Lum PJ et al. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology 34(1), 180-187 (2001).
62. Hutchinson SJ, Taylor A, Goldberg DJ et al. Factors associated with injecting risk behaviour among serial community-wide samples of injecting drug users in Glasgow 1990-1994: implications for control and prevention of blood-borne viruses. Addiction 95(6), 931-940 (2000).
63. Maher L, Li J, Jalaludin B et al. High hepatitis C incidence in new injecting drug users: a policy failure? Aust. NZ J. Public Health 31 (1), 30-35 (2007).
64. Alter MJ. Prevention of spread of hepatitis C. Hepatology 36(5 Suppl. 1), S93-S98 (2002).
65. Aceijas C, Friedman SR, Cooper HL, Wiessing L, Stimson GV, Hickman M. Estimates of injecting drug users at the national and local level in developing and transitional countries, and gender and age distribution. Sex. Transm. Infect. 82(Suppl. 3), iii10-iii17 (2006).
66. Thomas DL, Vlahov D, Solomon L et al. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) 74(4), 212-220 (1995).
67. Nguyen OK, Dore GJ, Kaldor JM et al.; ATAHC Protocol Steering Committee. Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: insights from the ATAHC study. Int. J. Drug Policy 18(5), 447-451 (2007).
68. Frank C, Mohamed MK, Strickland GT. et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 355(9207), 887-891 (2000).
69. Singh S, Dwivedi SN, Sood R, Wali JP. Hepatitis B, C and human immunodeficiency virus infections in multiply-injected kala-azar patients in Delhi. Scand. J. Infect Dis. 32(1), 3-6 (2000).
70. Kane A, Lloyd J, Zaffran M, Simonsen L, Kane M. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. Bull. World Health Organ. 77(10), 801-807 (1999).
71. Simonsen L, Kane A, Lloyd J, Zaffran M, Kane M. Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull. World Health Organ. 77(10), 789-800 (1999).
72. Yildirim B, Tahan V, Ozaras R et al. Hepatitis C virus risk factors in the Turkish community. Dig. Dis. Sci. 50(12), 2352-2355 (2005).
73. Tahan V, Karaca C, Yildirim B et al. Sexual transmission of HCV between spouses. Am. J. Gastroenterol. 100(4), 821-824 (2005).
74. Mert A, Ozaras R, Tabak F, Tahan V, Akdogan M, Senturk H. Spouses of HCV carriers are not at serious risk. Scand. J. Infect. Dis. 30(6), 644 (1998).
75. Recommendations for prevention and control ofhepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm. Rep. 47(RR-19), 1-39 (1998).
76. Thomas DL, Zenilman JM, Alter HJ et al. Sexual transmission of hepatitis C virus, among patients attending sexually transmitted diseases clinics in Baltimore - an analysis of 309 sex partnerships. J. Infect. Dis. 171(4), 768-775 (1995).
77. Danta M, Brown D, Bhagani S et al.; HIV and Acute HCV (HAAC) Group. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high risk sexual behaviours. AIDS 21(8), 983-991 (2007).
78. Gambotti L, Batisse D, Colin-de-Verdiere N et al; Acute Hepatitis C Collaborating Group. Acute hepatitis C infection in HIV positive men who have sex with men in Paris, France, 2001-2004. Euro. Surveill. 10(5), 115-117 (2005).
79. Sulkowski MS, Ray SC, Thomas DL. Needlestick transmission of hepatitis C. JAMA, 287(18), 2406-2413 (2002).
80. U.S. Public Health Service. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Recomm. Rep. 50(RR-11), 1-52 (2001).
81. Chung H, Kudo M, Kumada T et al. Risk of HCV transmission after needlestick injury, and the efficacy of short-duration interferon administration to prevent HCV transmission to medical personnel. J. Gastroenterol. 38(9), 877-879 (2003).
82. De Carli G, Puro V, Ippolito G; Studio Italiano Rischio Occupazionale da HIV Group. Risk of hepatitis C virus transmission following percutaneous exposure in healthcare workers. Infection 31(Suppl. 2), 22-27 (2003).
83. Patel PR, Larson AK, Castel AD et al. Hepatitis C virus infections from a contaminated radiopharmaceutical used in myocardial perfusion studies. JAMA 296(16), 2005-2011 (2006).
84. Santantonio T, Medda E, Ferrari C et al. Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy. Clin. Infect. Dis. 43(9), 1154-1159 (2006).
85. Martínez-Bauer E, Forns X, Armelles M et al.; Spanish Acute HCV Study Group. Hospital admission is a relevant source of hepatitis C virus acquisition in Spain. J. Hepatol. 48(1), 20-27 (2008).
86. Deterding K, Wiegand J, Grüner N et al. Medical procedures as a risk factor for HCV infection in developed countries: do we neglect a significant problem in medical care? J. Hepatol. 48(6), 1019-1020 (2008).
87. Olmer M, Bouchouareb D, Zandotti C et al. Transmission of the hepatitis C virus in an hemodialysis unit: evidence for nosocomial infection. Clin. Nephrol. 47(4), 263-270 (1997).
88. Minola E, Baldo V, Baldovin T et al. Intrafamilial transmission of hepatitis C virus infection. Eur. J. Epidemiol. 21(4), 293-297 (2006).
89. Mohamed MK, Abdel-Hamid M, Mikhail NN et al. Intrafamilial transmission of hepatitis C in Egypt. Hepatology 42(3), 683-687 (2005).
90. Tahan V, Yildirim B, Ture F et al. Anti-HCV seroprevalence in chronic HCV patients' children in Turkey. J. Clin. Gastroenterol. 38(1), 90-91 (2004).
91. Nomura H, Sou S, Tanimoto H et al. Short-term interferon-α therapy for acute hepatitis C: a randomized controlled trial. Hepatology 39(5), 1213-1219 (2004).
92. Cox AL, Netski DM, Mosbruger T et al. Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin. Infect. Dis. 40(7), 951-958 (2005).
93. Moore A, Herrera G, Nyamongo J et al. Estimated risk of HIV transmission by blood transfusion in Kenya. Lancet 358(9282), 657-660 (2001).
94. Mondelli MU, Cerino A, Cividini A. Acute hepatitis C: diagnosis and management. J. Hepatol. 42(Suppl. 1), S108-S114 (2005).
95. Farci P, Alter HJ, Wong D et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N. Engl. J. Med. 325(2), 98-104 (1991).
96. Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology 36(5 Suppl. 1), S65-S73 (2002).
97. Espinosa M, Martin-Malo A, Alvarez de Lara MA et al. Natural history of acute HCV infection in hemodialysis patients. Clin. Nephrol. 58, 143-150 (2002).
98. Engel M, Malta FM, Gomes MM et al. Acute hepatitis C virus infection assessment among chronic hemodialysis patients in the Southwest Parana State, Brazil. BMC Public Health 7, 50 (2007).
99. Al-Harbi AS, Malik GH, Subaity Y et al. Treatment of acute hepatitis C virus infection with α interferon in patients on hemodialysis. Saudi J. Kidney Dis. Transpl. 16, 293-297 (2005).
100. Ozaras R, Yilmaz M, Mete B, Demirel A, Tahan V. Recognizing acute hepatitis C in hemodialysis patients. Dig. Dis. Sci. 53(12), 3267-3268 (2008).
101. Myers RP, Regimbeau C, Thevenot T et al. Interferon for acute hepatitis C. Cochrane Database Syst. Rev. 4, CD000369 (2009).
102. National Institutes of Health Consensus Development Conference statement: management of hepatitis C: 2002. Gastroenterology 123(6), 2082-2099 (2002).
103. Alberti A, Boccato S, Vario A, Benvegnu L. I'Lerapy of acute hepatitis C. Hepatology 36(5 Suppl. 1), S195-S200 (2002).
104. Licata A, Di Bona D, Schepis F et al. When and how to treat acute hepatitis C? J. Hepatol. 39(6), 1056-1062 (2003).
105. Jaeckel E, Cornberg M, Wedemeyer H et al., German Acute Hepatitis C Therapy Group. Treatment of acute hepatitis C with interferon α-2b. N. Engl. J. Med. 345(20), 1452-1457 (2001).
106. Rocca P, Bailly F, Chevallier M et al. Early treatment of acute hepatitis C with interferon α-2b or interferon α -2b plus ribavirin: study of sixteen patients. Gastroenterol. Clin. Biol. 27(3 Pt 1), 294-299 (2003).
107. Takano S, Satomura Y, Omata M. Effects of interferon β on non-A, non-B acute hepatitis: a prospective, randomized, controlled-dose study. Japan Acute Hepatitis Cooperative Study Group. Gastroenterology 107(3), 805-811 (1994).
108. Kamal SM, Ismail A, Graham CS et al. Pegylated interferon a therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology 39, 1721-1731 (2004).
109. Dominguez S, Ghosn J, Valantin MA et al. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS 20(8), 1157-1161 (2006).
110. Calleri G, Cariti G, Gaiottino F et al. A short course of pegylated interferon-α in acute HCV hepatitis. J. Viral Hepat. 14, 116-121 (2007).
111. Kamal SM, Fouly AE, Kamel RR et al. Peginterferon α -2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 130(3), 632-638 (2006).
112. Wiegand J, Buggisch P, Boecher W et al. Early monotherapy with pegylated interferon α-2b for acute hepatitis infection: the HEP-NET acute-HCV-II study. Hepatology 43(2), 250-256 (2006).
113. Kamal SM, Moustafa KN, Chen J et al. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology 43(5), 923-931 (2006).
114. De Rosa FG, Bargiacchi O, Audagnotto S et al. Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon α-2b treatment for acute hepatitis C. J. Antimicrob. Chemother. 57(2), 360-363 (2006).
115. Broers B, Helbling B, Francois A et al. Swiss Association for the Study of the Liver (SASL 18). Barriers to interferon-α therapy are higher in intravenous drug users than in other patients with acute hepatitis C. J. Hepatol. 42(3), 323-328 (2005).